Phase 2 N=5 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Ovary Cancer · Cervix Cancer · Endometrium Cancer
Primary: Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE) — 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Metformin in Kidney Disease
Chronic Kidney Disease · Cardiovascular Disease · Metabolic Syndrome
Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms
Phase 2 N=23 Study of Topical SOR007 Ointment for Cutaneous Metastases
Cutaneous Metastasis
Primary: Incidence of Treatment Emergent Adverse Events — 4; 3; 5; 10 Participants
Phase 2 N=13 A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
C3 Glomerulopathy · C3 Glomerulonephritis · Dense Deposit Disease
Primary: Change From Baseline In Composite Biopsy Score At Week 28 — 11.7; 9.3; 9.2; 10.7 score on a scale
Phase 2 N=102 A Trial of Tisotumab Vedotin in Cervical Cancer
Cervical Cancer
Primary: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) — 23.8 Percentage of Participants — p=0.0002
Phase 2 N=25 A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
Jet Lag Disorder
Primary: Total Sleep Time in the First Two-Thirds of the Night on the Night(s) Most Likely to be Disrupted — 76.2; 41.4 minutes — p=0.0354
Phase 2 N=41 Biology and Experience of Eating in Women With Obesity
Obesity
Primary: Number of Participants Who Reported Nausea at 10 Minutes Post Treatment — 17; 18 Participants
Phase 2 N=30 Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair
Cleft Lip · Scarring · Cleft Palate
Primary: Hypertrophic Scarring (HTS) as Assessed by Score on the Manchester Scar Scale (MSS) Rated by Blinded Plastic Surgeons — 7; 9 score on a scale
Phase 2 N=3 Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial
Posttraumatic Stress Disorder
Primary: Baseline Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) — 93.3 score on a scale
Phase 2 N=257 PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer
Primary: Complete Pathological Response (pCR) of PET/CT Non-responders — 17.95; 20 percentage of participants with a pCR — p=1.0
Phase 2 N=27 Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
Lung Transplant Rejection · Antibody-mediated Rejection
Primary: Donor-specific HLA Antibodies, Re-transplantation, or Death — 0; 5; 3; 3 participants
Phase 2 N=21 Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
MSS · RAS-mutant Colorectal Cancer
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1; 2 Participants
Phase 2 N=11 Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
Hematogenously Acquired Staphylococcus Aureus Osteomyelitis · Bone Infection · Osteomyelitis
Primary: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to Adverse Events (AEs) — 1 incidence
Phase 2 N=38 A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes · Secondary Acute Myeloid Leukemia (AML)
Primary: Percentage of Participants With Overall Response — 13; 25 percentage of participants
Phase 2 N=139 Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis
Herpes Labialis · Cold Sore
Primary: Days to Next Herpes Labialis (Cold Sore) Episode From 43 Days After the First Dose up to 121 Days After the First Dose — 128; 163; 174 days